Oncoinvent ASA

Board/Management Information • Oct 31, 2025

Oncoinvent appoints Dr. Ramzi Amri as new CFO

Oncoinvent appoints Dr. Ramzi Amri as new CFO

Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri,

M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January.

Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. The company would

like to thank Mr Kvam for his valuable work and dedication over the past years.

"During his seven years in  Oncoinvent, Tore Kvam has worked tirelessly to

contribute to Oncoinvent's development and  performance. We're very grateful for

his contribution," says Øystein Soug, CEO of Oncoinvent.

Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as

Vice President and Head of Development Strategy & Execution. He brings broad

international experience through  leadership positions in strategy, operations,

and corporate transformation across the life sciences  and healthcare

industries. Dr. Amri also brings seven years of management consulting

experience  from McKinsey & Company, advising global pharma and biotech clients,

as well as financial  institutions and private-equity-backed businesses, on

growth, M&A, and organizationaltransformation.

Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He

conducted his Ph.D.  research and completed a postdoctoral fellowship in

surgical oncology and epidemiology at Harvard Medical School and Massachusetts

General Hospital, where he initiated and led a research program in colorectal

cancer.

"We are pleased to welcome Dr. Amri to Oncoinvent's management team," says

Øystein Soug, CEOof Oncoinvent. "His strategic and financial leadership,

together with deep industry knowledge, will be instrumental as we advance our

clinical programs and continue building long-term value for patients  and

shareholders alike."

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel

radiopharmaceutical  therapies against cancer. The lead product candidate,

Radspherin®, uses the alpha-emitting  radionuclide radium-224, directly

targeting micro-metastases in the peritoneum post-surgery,  harnessing the

benefits of modern radiopharmaceuticals without the complexities of biological

targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in

a clinical  development program in two indications. One Phase 1 trial and one

Phase 1/2a trial have been  completed and one randomized Phase 2 trial in

ovarian cancer is currently ongoing in the US and  Europe. Early clinical

efficacy data are highly encouraging, and no serious toxicity or safety concerns

have been reported to date. Oncoinvent runs a state-of-the-art manufacturing

facility to produce  drug products for clinical trials in Nydalen, Oslo.

Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly

target microscopic  metastases in the abdominal cavity following surgery.

Radspherin® is currently in development as a  post-surgical treatment for

patients with cancer that has spread to the abdominal cavity - a group  with

very limited treatment options today. The drug candidate offers a distinctly

unique therapeutic approach with several differentiating features, including the

use of radium-224, single-dose  treatment with a sustained therapeutic effect,

non-systemic administration, direct targeting and an  exceptional dose-to-tumor

ratio, maximizing efficacy while limiting harm to healthy tissue

Forward-Looking Statements

All statements other than statements of historical facts contained in this press

release are forward- looking statements and are not a representation that

Oncoinvent's plans, estimates, or expectations  will be achieved. These forward

-looking statements represent Oncoinvent's expectations as of the  date of this

press release, and Oncoinvent disclaims any obligation to update the forward

-looking  statements. These forward-looking statements are subject to known and

unknown risks and  uncertainties that may cause actual results to differ

materially, including with respect to whether the results of clinical or other

studies will support the use of our product offerings, the impact of results  of

such studies, our expectations of the reliability, accuracy and performance of

our tests, or of the  benefits of our tests and product offerings to patients,

providers and payers.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email:soug@oncoinvent.com  (soug@oncoinvent.com)